Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
521-540 of 847 trials

Advanced Solid Tumors: VERT-002 Study

We are studying a new anticancer drug, VERT-002, for patients with advanced solid tumors, including lung cancer with MET alterations. The trial aims to assess its safety and how well it may work.

Metastatic Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Facial Lines: IPN10200 Treatment Study

We are studying a new treatment for adults with moderate to severe upper facial lines to see if it improves their appearance compared to a placebo. The trial will assess both safety and effectiveness of the treatment.

Frown Lines6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesDermatology

Lung Fibrosis: Nerandomilast Study

We are testing whether nerandomilast can improve lung function in people with lung fibrosis related to rheumatic diseases. The study will also look at safety, including the risk of infections.

Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPulmonologyRheumatology

Generalized Myasthenia Gravis: DNTH103 Treatment Study

We are testing a new treatment called DNTH103 for adults with generalized myasthenia gravis. The study aims to evaluate its safety, tolerability, and effectiveness in managing symptoms.

Myasthenia Gravis3-6 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Primary Adrenal Insufficiency: Plenadren vs. Cortisone

We are investigating how treatment with Plenadren affects quality of life compared to cortisone in individuals aged 16-80 newly diagnosed with primary adrenal insufficiency.

Primary Adrenal Insufficiency>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinology

Bladder Cancer: EG-70 Treatment Study

We are testing a new treatment called EG-70 for patients with bladder cancer that hasn't responded to standard therapy. The study aims to see if it can help improve outcomes and quality of life for these patients.

Non-muscle invasive bladder cancer>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyUrology

Advanced Breast Cancer: PF-07220060 with Letrozole

We are studying a new medicine, PF-07220060, combined with letrozole for adults with HR-positive, HER2-negative advanced breast cancer. This trial compares its effectiveness to standard treatments in patients who haven't had prior systemic therapy.

Advanced/Metastatic Breast CancerConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Menstrual Migraine: Atogepant Study

We are testing Atogepant to see if it can help prevent menstrual migraines. The study will also look at its safety and how well people tolerate the treatment.

Menstrual Migraine6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementGynecology and ObstetricsNeurology

Ovarian Cancer: Continued Treatment with Olaparib

We are providing ongoing treatment with Olaparib for patients who have benefited from it in a previous study. This trial focuses on monitoring safety while allowing continued access to the medication.

Ovarian CancerBreast CancerProstate Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

ENPP1 Deficiency: INZ-701 Study

We are investigating whether the drug INZ-701 can help infants with ENPP1 deficiency by improving survival and preventing heart and respiratory problems. The study aims to see if it can also support physical growth and reduce artery issues.

Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Non-Small Cell Lung Cancer: Acasunlimab and Pembrolizumab Study

We are evaluating a new combination treatment for patients with advanced non-small cell lung cancer who have already received other therapies. The goal is to see if this combination works better than the standard treatment, docetaxel.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Advanced Solid Tumors: OATD-02 Treatment

We are evaluating the safety and potential effectiveness of OATD-02 in patients with advanced or metastatic solid tumors who have completed an earlier study. This research aims to understand how well this treatment works in this specific group.

Advanced Solid Tumors>2 yearsSafety phase (I)Post-Trial Drug AccessOncology

Ulcerative Colitis: RO7790121 Treatment Study

We are studying a new treatment for people with moderately to severely active ulcerative colitis to see if it can help induce remission. The trial will also assess its safety and impact on symptoms and quality of life.

Ulcerative ColitisConfirmation phase (III)Post-Trial Drug AccessCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Juvenile Idiopathic Arthritis: MOVE-JIA Trial

We are comparing two treatment withdrawal strategies for children and adolescents with Juvenile Idiopathic Arthritis in remission. The goal is to see which method better prevents disease flares compared to ongoing stable treatment.

Juvenile Idiopathic Arthritis>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Invasive Aspergillosis: Olorofim vs. AmBisome®

We are studying a new treatment called olorofim for patients with invasive aspergillosis to see if it works better and is safer than the standard treatment, AmBisome®. This trial will also look at how these treatments affect patients' quality of life.

Invasive Fungal Infection3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Crohn's Disease: RO7790121 Treatment Study

We are evaluating a new treatment for people with moderately to severely active Crohn's disease to see if it helps improve symptoms and quality of life compared to a placebo.

Moderately to Severely Active Crohn's DiseaseConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Tuberous Sclerosis Complex: Vigabatrin vs. Rapamycin

We are comparing the safety and effectiveness of two medications, vigabatrin and rapamycin, in preventing symptoms of Tuberous Sclerosis Complex in infants. This study aims to understand how these treatments affect epilepsy severity and overall quality of life.

Tuberous Sclerosis Complex>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyPediatrics

Psoriatic Arthritis: Zasocitinib Study

We are testing a new medication, Zasocitinib, for people with active psoriatic arthritis to see if it improves symptoms better than a placebo. The study also looks at how it affects daily life and physical function.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementRheumatology

Multifocal Motor Neuropathy: DNTH103 Treatment Study

We are testing a new treatment, DNTH103, for adults with multifocal motor neuropathy to see if it improves muscle strength and quality of life. The study will also check its safety compared to a placebo.

Multifocal Motor Neuropathy1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Hypochondroplasia: Vosoritide Treatment Study

We are testing a new medication, vosoritide, to see if it helps children with hypochondroplasia grow taller compared to a placebo. The study aims to evaluate its effects on growth velocity and height.

Hypochondroplasia1-2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemotePediatrics